Krystal Biotech Inc (KRYS) - Total Assets
Based on the latest financial reports, Krystal Biotech Inc (KRYS) holds total assets worth $1.24 Billion USD as of September 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See shareholders equity of Krystal Biotech Inc for net asset value and shareholders' equity analysis.
Krystal Biotech Inc - Total Assets Trend (2016–2024)
This chart illustrates how Krystal Biotech Inc's total assets have evolved over time, based on quarterly financial data.
Krystal Biotech Inc - Asset Composition Analysis
Current Asset Composition (December 2024)
Krystal Biotech Inc's total assets of $1.24 Billion consist of 70.3% current assets and 29.7% non-current assets.
| Asset Category | Amount (USD) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | $0.00 | 32.7% |
| Accounts Receivable | $104.75 Million | 9.9% |
| Inventory | $26.51 Million | 2.5% |
| Property, Plant & Equipment | $0.00 | 0.0% |
| Intangible Assets | $0.00 | 0.0% |
| Goodwill | $0.00 | 0.0% |
Asset Composition Trend (2016–2024)
This chart illustrates how Krystal Biotech Inc's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see Krystal Biotech Inc market capitalisation.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Krystal Biotech Inc's current assets represent 70.3% of total assets in 2024, a decrease from 99.4% in 2016.
- Cash Position: Cash and equivalents constituted 32.7% of total assets in 2024, down from 88.1% in 2016.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 0.0% of total assets, unchanged from 0.0% in 2016.
- Asset Diversification: The largest asset category is accounts receivable at 9.9% of total assets.
Krystal Biotech Inc Competitors by Total Assets
Key competitors of Krystal Biotech Inc based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Fortress Biotech Inc
NASDAQ:FBIO
|
USA | $185.55 Million |
|
Summit Therapeutics PLC
NASDAQ:SMMT
|
USA | $261.73 Million |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
Apellis Pharmaceuticals Inc
NASDAQ:APLS
|
USA | $1.08 Billion |
|
Beijing Tiantan Biological Products Corp Ltd
SHG:600161
|
China | CN¥16.55 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
BioArctic AB (publ)
ST:BIOA-B
|
Sweden | Skr2.60 Billion |
|
Chengzhi Shareholding Co Ltd
SHE:000990
|
China | CN¥27.52 Billion |
Krystal Biotech Inc - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 10.14 | 7.97 | 17.80 |
| Quick Ratio | 9.73 | 7.76 | 17.80 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | $834.38 Million | $623.64 Million | $259.61 Million |
Krystal Biotech Inc - Advanced Valuation Insights
This section examines the relationship between Krystal Biotech Inc's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 7.05 |
| Latest Market Cap to Assets Ratio | 7.31 |
| Asset Growth Rate (YoY) | 29.0% |
| Total Assets | $1.06 Billion |
| Market Capitalization | $7.71 Billion USD |
Valuation Analysis
Premium Asset Valuation: The market values Krystal Biotech Inc's assets at a significant premium (7.31x), suggesting investors see substantial growth potential or unique competitive advantages.
Rapid Asset Growth: Krystal Biotech Inc's assets grew by 29.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Krystal Biotech Inc (2016–2024)
The table below shows the annual total assets of Krystal Biotech Inc from 2016 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | $1.06 Billion | +29.02% |
| 2023-12-31 | $818.36 Million | +46.54% |
| 2022-12-31 | $558.45 Million | -10.83% |
| 2021-12-31 | $626.29 Million | +101.48% |
| 2020-12-31 | $310.84 Million | +48.71% |
| 2019-12-31 | $209.02 Million | +80.01% |
| 2018-12-31 | $116.12 Million | +131.70% |
| 2017-12-31 | $50.11 Million | +2196.70% |
| 2016-12-31 | $2.18 Million | -- |
About Krystal Biotech Inc
Krystal Biotech, Inc., a commercial-stage biotechnology company, discovers, develops, manufactures, and commercializes genetic medicines to treat diseases with high unmet medical needs in the United States. The company commercializes VYJUVEK (beremagene geperpavec-svdt, or B-VEC) for the treatment of dystrophic epidermolysis bullosa (DEB). It also develops KB105, which is in Phase 1/2 clinical tr… Read more